Biograil has raised 20M euros to keep developing a capsule that delivers biologics without a needle. The Copenhagen company announced the close on November 4, with Verve Ventures and Megatrend Invest backing the round and German investor HTGF joining through its Opportunity growth fund.
HTGF led Biograil’s seed syndicate in 2019 and Verve had already led an 8.5M euro first close in July 2025, so this is a team most backers have known for years.
How a pill replaces a syringe
The device, branded BIONDD, sits inside a standard double-zero or single-zero capsule a patient can swallow. Once the shell dissolves, a spring-loaded mechanism grabs the stomach wall and releases medication into the tissue for systemic distribution.
It is produced by injection moulding and designed to be bio-compostable, passing safely through the digestive tract afterward. That manufacturing choice matters at scale: the team includes executives behind the first injection-moulded oral tablet approved by the US Food and Drug Administration.
The commercial logic is simple. A large share of modern biologics are injected, pushing patients into clinics, adding cold-chain costs and creating adherence problems. Turning even a fraction of them into a swallowed pill opens a far bigger market than the devices themselves.
The regulatory road ahead
Capital goes toward the groundwork for a Phase 1 trial: non-clinical GLP studies and a GMP manufacturing process, both prerequisites before a larger financing in 2027.
Chief executive Karsten Lindhardt called the raise validation from existing backers plus growth capital from HTGF, combined with non-diluting partnership funding.
Drug delivery is slow and capital-hungry, and clinical failures are common. Biograil’s bet is that a mechanical answer to a formulation problem can move faster than the biology it replaces.
